{"contentid": 488598, "importid": NaN, "name": "Takeda delivers resilient FY2020 financials", "introduction": "Japan\u00e2\u0080\u0099s largest drugmaker Takeda Pharmaceutical today announced financial results for fiscal year 2020 (period ended March 31, 2021), which the company says demonstrate its \u00e2\u0080\u009cresilient portfolio.\u00e2\u0080\u009d", "content": "<p>Japan&rsquo;s largest drugmaker Takeda Pharmaceutical (TYO: 4502) today announced financial results for fiscal year 2020 (period ended March 31, 2021), which the company says demonstrate its &ldquo;resilient portfolio.&rdquo;</p>\n<p>Reported revenues at 3,197.8 billion yen (~$28.9 billion), declined by 2.8% impacted primarily by foreign exchange and divestitures. Underlying revenues growth in FY2020 was +2.2% driven by the growth of Takeda&rsquo;s 14 global brands, up 16% year-on-year</p>\n<p>Takeda delivered reported operating profit of 509.3 billion yen (~$4.6 billion), which grew 407.2% with gains from non-core asset sales and acquisition-related expenses. Core operating profit, which adjusts for purchase price accounting (PPA) and non-recurring items (including gains on sales of assets), increased year-on-year to JPY 967.9 billion yen (~$8.8 billion). Takeda&rsquo;s reported net profit was 376 billion yen, a 749.9% increase compared with the same period in the prior year.</p>\n<h2><strong>FY2021 forecast</strong></h2>\n<p>Reported revenue is forecast to be 3,370 billion yen, a year-on-year increase of 172.2 billion yen or +5.4% from FY2020, with underlying revenue momentum and a one-time gain from the sale of diabetes portfolio in Japan fully offsetting impacts from divestitures completed in FY2020.</p>\n<p>Underlying core operating profit and underlying core earnings per share (EPS) are expected to also grow at &ldquo;mid-single-digit,&rdquo; reflecting revenue growth and continued cost efficiencies, whilst also incorporating a significant increase in R&amp;D expenses to support Takeda&rsquo;s innovative pipeline.</p>\n<p>Christophe Weber, Takeda&rsquo;s president and chief executive, commented: &ldquo;Over the course of FY2020, Takeda remained resilient as we operated in new ways through the COVID-19 pandemic. This is a testament to the dedication of our employees, and Takeda&rsquo;s unwavering commitment to serving patients, our people, and the planet to bring <em>better health for people and a brighter future for the world</em>. We maintained business continuity, ensured patient access to our medicines and safeguarded the health and well-being of our employees while helping to address the pandemic.</p>\n<p>&ldquo;With FY2021 anticipated to serve as a critical inflection year, we remain focused on leveraging our expected top-line growth to ramp up our R&amp;D investment and further fuel our transformative pipeline. We are well-positioned to reach our goal of mid-single-digit revenue growth over the next decade amounting to 5 trillion yen ($47 billion) by FY2030.</p>\n<h2><strong>Global brand highlights&nbsp;&nbsp;&nbsp;</strong></h2>\n<table width=\"100%\">\n<tbody>\n<tr>\n<td width=\"209\">\n<p><strong>Business area</strong></p>\n</td>\n<td width=\"230\">\n<p><strong>Product</strong></p>\n</td>\n<td width=\"206\">\n<p><strong>Reported product revenue</strong><br /> <strong>Yen (billion)</strong></p>\n</td>\n<td width=\"239\">\n<p><strong>Year-over-year underlying</strong><br /> <strong>revenue growth</strong></p>\n</td>\n</tr>\n<tr>\n<td width=\"209\">\n<p>Gastroenterology</p>\n</td>\n<td width=\"230\">\n<p>Entyvio (vedolizumab)</p>\n</td>\n<td width=\"206\">\n<p>429.3</p>\n</td>\n<td width=\"239\">\n<p>+26.2%</p>\n</td>\n</tr>\n<tr>\n<td width=\"209\">\n<p>Rare diseases</p>\n</td>\n<td width=\"230\">\n<p>Takhzyro (lanadelumab-flyo)</p>\n</td>\n<td width=\"206\">\n<p>86.7</p>\n</td>\n<td width=\"239\">\n<p>+30.0%</p>\n</td>\n</tr>\n<tr>\n<td width=\"209\">\n<p>PDT Immunology</p>\n</td>\n<td width=\"230\">\n<p>Immunoglobulin</p>\n</td>\n<td width=\"206\">\n<p>334.9</p>\n</td>\n<td width=\"239\">\n<p>+15.7%</p>\n</td>\n</tr>\n<tr>\n<td width=\"209\">\n<p>Oncology</p>\n</td>\n<td width=\"230\">\n<p>Ninlaro (ixazomib)</p>\n</td>\n<td width=\"206\">\n<p>87.4</p>\n</td>\n<td width=\"239\">\n<p>+15.9%</p>\n</td>\n</tr>\n<tr>\n<td width=\"209\">\n<p>Oncology</p>\n</td>\n<td width=\"230\">\n<p>Alunbrig (brigatinib)</p>\n</td>\n<td width=\"206\">\n<p>8.8</p>\n</td>\n<td width=\"239\">\n<p>+24.4%</p>\n</td>\n</tr>\n</tbody>\n</table>\n<p>&nbsp;</p>", "date": "2021-05-11 14:07:00", "meta_title": "Takeda delivers resilient FY2020 financials", "meta_keywords": "Takeda, Financial results, Fiscal year, 2020, March 31, 2021, Entyvio, Takhzyro, Ninlaro, Alunbrig", "meta_description": "Takeda delivers resilient FY2020 financials", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-05-11 14:00:48", "updated": "2021-05-11 14:10:32", "access": NaN, "url": "https://www.thepharmaletter.com/article/takeda-delivers-resilient-fy2020-financials", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "takeda_corporate_building_large.jpg", "image2id": "takeda_corporate_building_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Pharmaceutical", "therapy area_tag": "Gastroenterology, Immunologicals, Oncology, Rare diseases", "topic_tag": "Financial, Management", "geography_tag": "Japan", "company_tag": "Takeda", "drug_tag": "Alunbrig, Entyvio, Ninlaro, Takhzyro", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-05-11 14:07:00"}